Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.
Abortion, Spontaneous
/ chemically induced
Administration, Oral
Adolescent
Adult
Antifungal Agents
/ administration & dosage
Candidiasis, Vulvovaginal
/ drug therapy
Case-Control Studies
Cohort Studies
Female
Fluconazole
/ administration & dosage
Gestational Age
Heart Septal Defects
/ chemically induced
Humans
Logistic Models
Maternal Exposure
/ adverse effects
Multivariate Analysis
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Pregnancy Trimester, First
Quebec
/ epidemiology
Stillbirth
/ epidemiology
Young Adult
Journal
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
ISSN: 1488-2329
Titre abrégé: CMAJ
Pays: Canada
ID NLM: 9711805
Informations de publication
Date de publication:
19 02 2019
19 02 2019
Historique:
accepted:
22
01
2019
entrez:
21
2
2019
pubmed:
21
2
2019
medline:
23
11
2019
Statut:
ppublish
Résumé
While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. We aimed to assess the effect of exposure to low and high doses of fluconazole during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths. Within the Quebec Pregnancy Cohort (1998-2015), we identified women exposed to low- (≤ 150 mg) and high-dose (> 150 mg) fluconazole, and women who were not exposed. For each case of spontaneous abortion or stillbirth, up to 5 controls were randomly selected using an incidence density sampling method matched on gestational age at diagnosis of spontaneous abortion or stillbirth (index date) and the year of the last menstrual period. For cases of major congenital malformation, we considered all liveborn babies as controls. Generalized estimation equation models were used to analyze the 3 main outcomes separately. Within a cohort of 441 949 pregnancies, 320 868 pregnancies were included in the analyses of spontaneous abortions, 226 599 of major congenital malformations and 7832 of stillbirths. Most (69.5%) women exposed to fluconazole in pregnancy received the common single therapeutic dose of 150 mg (low dose); the remainder received a dose of > 150 mg (high dose). Use of oral fluconazole during early pregnancy was associated with an increased risk of spontaneous abortion compared with no exposure (adjusted odds ratio [OR] for 345 cases exposed to low-dose treatment 2.23, 95% confidence interval [CI] 1.96-2.54; adjusted OR for 249 cases exposed to high-dose treatment 3.20, 95% CI 2.73-3.75). Exposure to fluconazole during the first trimester did not increase the risk of overall major congenital malformations; however, exposure to a high dose during the first trimester was associated with an increased risk of cardiac septal closure anomalies (adjusted OR 1.81, 95% CI 1.04-3.14; 13 exposed cases) compared with no exposure. No association was found between exposure to fluconazole during pregnancy and the risk of stillbirth. Any maternal exposure to fluconazole during pregnancy may increase risk of spontaneous abortion and doses higher than 150 mg during the first trimester may increase risk of cardiac septal closure anomalies.
Sections du résumé
BACKGROUND
While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. We aimed to assess the effect of exposure to low and high doses of fluconazole during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths.
METHODS
Within the Quebec Pregnancy Cohort (1998-2015), we identified women exposed to low- (≤ 150 mg) and high-dose (> 150 mg) fluconazole, and women who were not exposed. For each case of spontaneous abortion or stillbirth, up to 5 controls were randomly selected using an incidence density sampling method matched on gestational age at diagnosis of spontaneous abortion or stillbirth (index date) and the year of the last menstrual period. For cases of major congenital malformation, we considered all liveborn babies as controls. Generalized estimation equation models were used to analyze the 3 main outcomes separately.
RESULTS
Within a cohort of 441 949 pregnancies, 320 868 pregnancies were included in the analyses of spontaneous abortions, 226 599 of major congenital malformations and 7832 of stillbirths. Most (69.5%) women exposed to fluconazole in pregnancy received the common single therapeutic dose of 150 mg (low dose); the remainder received a dose of > 150 mg (high dose). Use of oral fluconazole during early pregnancy was associated with an increased risk of spontaneous abortion compared with no exposure (adjusted odds ratio [OR] for 345 cases exposed to low-dose treatment 2.23, 95% confidence interval [CI] 1.96-2.54; adjusted OR for 249 cases exposed to high-dose treatment 3.20, 95% CI 2.73-3.75). Exposure to fluconazole during the first trimester did not increase the risk of overall major congenital malformations; however, exposure to a high dose during the first trimester was associated with an increased risk of cardiac septal closure anomalies (adjusted OR 1.81, 95% CI 1.04-3.14; 13 exposed cases) compared with no exposure. No association was found between exposure to fluconazole during pregnancy and the risk of stillbirth.
INTERPRETATION
Any maternal exposure to fluconazole during pregnancy may increase risk of spontaneous abortion and doses higher than 150 mg during the first trimester may increase risk of cardiac septal closure anomalies.
Identifiants
pubmed: 30782643
pii: 191/7/E179
doi: 10.1503/cmaj.180963
pmc: PMC6379167
doi:
Substances chimiques
Antifungal Agents
0
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E179-E187Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
Competing interests: Anick Bérard reports receiving grants from the Canadian Institutes of Health Research (the Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research), the Fonds de la recherche du Québec–santé, and the Réseau québécois de recherche sur les médicaments, during the conduct of the study. No other competing interests were declared.
Références
J Lipid Res. 2011 Jan;52(1):6-34
pubmed: 20929975
World Health Stat Q. 1988;41(1):32-6
pubmed: 3376487
Pediatr Neonatol. 2015 Jun;56(3):183-8
pubmed: 25544042
CMAJ. 2010 Jul 13;182(10):1031-7
pubmed: 20513781
BJOG. 2009 Dec;116(13):1788-95
pubmed: 19832828
Practitioner. 1985 Jul;229(1405):655-60
pubmed: 4034475
MMWR Recomm Rep. 2002 May 10;51(RR-6):1-78
pubmed: 12184549
Am J Obstet Gynecol. 1998 Feb;178(2):374-80
pubmed: 9500502
J Biol Chem. 2011 Aug 19;286(33):29086-29097
pubmed: 21705796
J Allergy Clin Immunol. 2016 Jul;138(1):97-104.e7
pubmed: 27045580
JAMA. 2016 Jan 5;315(1):58-67
pubmed: 26746458
Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):345-53
pubmed: 18271060
J Antimicrob Chemother. 2008 Jul;62(1):172-6
pubmed: 18400803
Sociol Methods Res. 2013 Nov 1;42(4):
pubmed: 24223447
Eur J Clin Pharmacol. 1994;46(2):115-8
pubmed: 8039528
Antimicrob Agents Chemother. 1987 Jan;31(1):46-51
pubmed: 3551826
Res Commun Chem Pathol Pharmacol. 1993 Mar;79(3):381-4
pubmed: 8480084
Am J Med Genet. 1997 Oct 31;72(3):253-6
pubmed: 9332650
Birth Defects Res. 2017 Apr 3;109(6):423-431
pubmed: 28398706
Ann Pharmacother. 1997 Jan;31(1):118-9
pubmed: 8997479
Pharmacotherapy. 1999 Feb;19(2):221-2
pubmed: 10030772
Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):881-9
pubmed: 23616437
PLoS One. 2014 Apr 04;9(4):e93870
pubmed: 24705674
Am J Med Genet A. 2004 Aug 1;128A(4):333-9
pubmed: 15264278
Can J Clin Pharmacol. 2009 Summer;16(2):e360-9
pubmed: 19553702
Birth Defects Res A Clin Mol Teratol. 2005 Nov;73(11):919-23
pubmed: 16265639
N Engl J Med. 2013 Aug 29;369(9):830-9
pubmed: 23984730
JAMA. 2018 Jun 12;319(22):2333-2335
pubmed: 29896619
Clin Infect Dis. 1996 Feb;22(2):336-40
pubmed: 8838193
J Obstet Gynaecol Can. 2015 Mar;37(3):266-274
pubmed: 26001874
Rev Obstet Gynecol. 2009 Spring;2(2):76-83
pubmed: 19609401
Am J Obstet Gynecol. 2016 May;214(5):657.e1-9
pubmed: 26640069
Birth Defects Res A Clin Mol Teratol. 2003 Feb;67(2):116-24
pubmed: 12769507
Br J Clin Pharmacol. 1999 Aug;48(2):234-8
pubmed: 10417502
Lancet. 2007 Jun 9;369(9577):1961-71
pubmed: 17560449
Pain. 2018 May;159(5):948-955
pubmed: 29351170
Am J Obstet Gynecol. 1996 Dec;175(6):1645-50
pubmed: 8987954
J Popul Ther Clin Pharmacol. 2015;22(3):e198-210
pubmed: 26567551
CMAJ. 2017 May 1;189(17):E625-E633
pubmed: 28461374
BMJ Open. 2017 Jan 12;7(1):e013372
pubmed: 28082367
MMWR Recomm Rep. 2006 Aug 4;55(RR-11):1-94
pubmed: 16888612
J Clin Epidemiol. 2014 Aug;67(8):850-7
pubmed: 24831050
Pediatr Infect Dis J. 1992 Dec;11(12):1062-4
pubmed: 1461702
N Engl J Med. 2006 Sep 21;355(12):1244-52
pubmed: 16990387
CMAJ. 2011 Oct 18;183(15):1713-20
pubmed: 21896698